Astra field action creates $75M revenue headwind in FY27
ResMed reported strong Q4 FY26 results with 9% revenue growth and 16% EPS growth, driven by volume rather than price. The company provided its first-ever annual guidance for FY27, projecting continued growth and significant capital returns, while navigating the ASTRAL field action and portfolio changes. Q4 FY26 revenue hit $1.5 billion (+9% YoY), EPS $2.95 (+16%), driven by volume and productivity.
Buzzberg readAstra field action creates $75M revenue headwind in FY27ResMed reported strong Q4 FY26 results with 9% revenue growth and 16% EPS growth, driven by volume rather than price. The company provided its first-ever annual guidance for FY27, projecting continued growth and significant capital returns, while navigating the ASTRAL field action and portfolio changes. Q4 FY26 revenue hit $1.5 billion (+9% YoY), EPS $2.95 (+16%), driven by volume and productivity.Read full analysisCollapse analysis
ResMed reported strong Q4 FY26 results with 9% revenue growth and 16% EPS growth, driven by volume rather than price. The company provided its first-ever annual guidance for FY27, projecting continued growth and significant capital returns, while navigating the ASTRAL field action and portfolio changes. Q4 FY26 revenue hit $1.5 billion (+9% YoY), EPS $2.95 (+16%), driven by volume and productivity.
Initiated FY27 guidance: 5%-7% core constant currency revenue growth, total EPS $12-$12.25, with gross margin expansion.
ASTRAL field safety action: $42 million provision in Q4; $75 million revenue headwind for FY27 due to suspended sales to prioritize patient safety.
Revenue$1.4636B
+2% QoQ
EPS$2.95
+3% QoQ
Gross margin58.84%
reported
Op margin30.66%
reported
What changed this quarter
01
Guidance
Astra field action creates $75M revenue headwind in FY27
Guidance · revenue to $5.8B
02
Demand
GLP-1s increase CPAP initiation and adherence
Demand remains strong, with core sleep device revenue growth of 8% in the Americas and 13% rest of world, exceeding market growth expectations. Partnerships and wearables are driving increased awareness and funnel growth, with 75% of assessed users from the Aura partnership…
03
Portfolio
MatrixCare divestiture sharpens focus on core growth
Noctrix acquisition expands into restless legs syndrome
Initiated FY27 guidance: 5%-7% core constant currency revenue growth, total EPS $12-$12.25, with gross margin expansion.
AI, capex & demand read
AI
Platform & monetization
Management highlighted significant AI-driven initiatives, including a Gen AI-powered digital sleep coach in the MyAir app with 1.5 million inquiries, which reduced customer service inquiries, and FDA-approved AI features like SmartComfort and Dawn. They are investing in AI-driven patient workflow solutions.
Demand
Bookings & conversion
Demand remains strong, with core sleep device revenue growth of 8% in the Americas and 13% rest of world, exceeding market growth expectations. Partnerships and wearables are driving increased awareness and funnel growth, with 75% of assessed users from the Aura partnership being previously undiagnosed.
Capex
Investment and capacity
Capital expenditures are expected to increase to $160-180 million as they expand and further automate U.S. and global manufacturing, reflecting confidence in future demand.
Tone · Confident
Management expressed confidence in growth prospects, citing strong execution, expanded transparency, and a clear strategy for 2027.
Bottlenecks
Componentspersistent
Electronic components and freight costs are facing inflation, impacting gross margins.
Inflation pressure may persist into FY27, though offset by productivity and modest price increases.
“it's primarily driven by the increased inflation that we're starting to see, particularly in electronic components and freight costs.”
Expanding and automating US and global manufacturing footprint to address growing demand.
Capacity expansion is necessary to support growth, and timing of benefits may affect margins.
“We expect a step up in our capital expenditures to a range of 160 to 180 million as we expand and further automate our U.S. and global manufacturing footprint to address the growing demand of our products.”
ResMed generated $1.6 billion in free cash flow for fiscal year 2026, a key indicator of financial health.
“For fiscal year 2026, our 10% headline revenue growth and 180 basis points of operating margin expansion drove more than $1.6 billion in free cash flow.”
The gross margin guide of 'low double-digit expansion' and 'very modest price increases' indicates that the company's growth is more volume-driven than pricing-oriented.
“I think one helpful piece, if you wanted to try to analyze it, would be kind of look at our gross margin guide... low double-digit increases in our gross margin and very modest price increases.”
The decision to suspend sales of ASTRAL for all of fiscal year 2027 due to the field safety notice reduces top-line growth by 130 basis points (~$75 million).
“This includes an approximately 130 basis headwind, or around $75 million, stemming from our decision to suspend sales of Astral...”
ResMed's partnership with Aura and the Samsung Galaxy Ring's FDA pursuit for sleep apnea detection will likely increase consumer awareness and funnel more patients into the sleep health market.
“Early performance from our Aura partnership has exceeded expectations. Approximately 13,000 users have come to ResMed.com from the Aura app... Approximately 75% of those assessed identifying as previously undiagnosed.”
Samsung's Galaxy Ring entry into sleep apnea detection validates the sleep health market and could drive more patients into the funnel, benefiting ResMed's core business.
“Samsung has just announced that its Galaxy Ring is pursuing FDA clearance for its sleep apnea detection capability later this year.”
… care. Early performance from our Aura partnership has exceeded expectations. Approximately 13,000 users have come to ResMed.com from the Aura app, with thousands of them taking the ResMed sleep assessment and approximately 75% of those assessed identifying as previously undiagnosed. This highlights the potential of consumer wearables to drive earlier sleep health intervention. As another example of tech companies involved with sleep health, Samsung has just announced that its Galaxy Ring is pursuing FDA clearance for its sleep apnea detection capability later this year. Another sleep pathway enabler are glucogen-like peptides or GLP-1s. As we've discussed before, patients on GLP-1s both initiate CPAP more and stay on CPAP therapy with a higher adherence and resupply rate. As an update to our analysis built from a claims database of many tens of millions of patients, our specifically analyzed cohort now includes more than N equals 2.5 million de-identified patients. We are still seeing that patients who have scripts for both PAP and GLP-1s are approximately 11% more likely to start on PAP therapy than patients who have a script for PAP alone. They also more than 3% more likely …
The Aura partnership is a new demand-generation channel for ResMed, successfully converting consumer sleep tracking interest into clinical assessments and new patient identification.
ResMed's aggressive approach to its ASTRAL field safety action, while costly, likely strengthens its reputation as a patient-first company relative to competitors with similar issues.
… and beyond. We additionally just launched the Aircurve 11 platform in Hong Kong, Singapore, Australia and New Zealand. We continue to see opportunities to leverage a shared technology and digital health ecosystem across a broader range of patient populations, helping simplify workflows for providers while creating a more consistent experience for patients. Prioritising patient care is also central to our ongoing ASTRAL Field Safety Corrective Action. We reaffirm our commitment to supporting patients as our number one priority, period. Patients come first. This includes patient-centric and quality-focused completion of the ongoing field action, while providing home care provider customers with the certainty needed to plan for future ventilation needs. We are focusing all available PCBA and other electronic components on corrective activities and service support for existing patients, prioritising based on the highest clinical need and guided by expert clinical judgment. Aaron will discuss the financial considerations as part of our fiscal year 2027 guidance in a few minutes. Beyond our device updates, we've continued our global rollout of our portfolio of novel fabric …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.